人体接种流感病毒后的抗体反应。
THE ANTIBODY RESPONSE OF HUMAN SUBJECTS VACCINATED WITH THE VIRUS OF HUMAN INFLUENZA.
机构信息
Laboratories of the International Health Division, the Rockefeller Foundation, New York.
出版信息
J Exp Med. 1937 Jan 31;65(2):251-9. doi: 10.1084/jem.65.2.251.
Abstract
Human influenza virus cultivated in tissue culture medium may be administered subcutaneously or intradermally to human individuals without causing evidence of infection. Subjects so treated develop a good titer of circulating antibodies effective against mouse passage virus and, if antibodies were previously present, vaccination stimulates the production of more antibody. The antibodies so induced persist for at least 5 months, although in this period of time some decline in titer may have begun. The antibody response to vaccination parallels both in extent and persistence that occurring as a result of the naturally acquired disease. The available data do not enable one to evaluate the effect of vaccination in preventing human infection with influenza. It seems not unlikely that the increase in circulating antibody will be accompanied by an increased ability to combat the natural infection.
摘要
在组织培养介质中培养的人流感病毒可以通过皮下或皮内途径给予人类个体而不引起感染的证据。接受这种治疗的受试者会产生针对鼠传病毒的循环抗体的良好效价，并且如果之前存在抗体，疫苗接种会刺激更多抗体的产生。诱导的抗体至少持续 5 个月，尽管在此期间效价可能已经开始下降。疫苗接种引起的抗体反应在程度和持久性上与自然获得性疾病的反应相似。现有数据使人无法评估疫苗接种在预防人类流感感染方面的效果。增加循环抗体似乎不太可能伴随着对抗自然感染的能力的提高。
相似文献
1
THE ANTIBODY RESPONSE OF HUMAN SUBJECTS VACCINATED WITH THE VIRUS OF HUMAN INFLUENZA.人体接种流感病毒后的抗体反应。
J Exp Med. 1937 Jan 31;65(2):251-9. doi: 10.1084/jem.65.2.251.
2
Persistence of Antibodies to Influenza Hemagglutinin and Neuraminidase Following One or Two Years of Influenza Vaccination.流感疫苗接种一至两年后针对流感血凝素和神经氨酸酶抗体的持久性
J Infect Dis. 2015 Dec 15;212(12):1914-22. doi: 10.1093/infdis/jiv313. Epub 2015 May 26.
3
Evaluation of Preexisting Anti-Hemagglutinin Stalk Antibody as a Correlate of Protection in a Healthy Volunteer Challenge with Influenza A/H1N1pdm Virus.评估健康志愿者挑战甲型流感病毒 A/H1N1pdm 时预先存在的抗血凝素茎部抗体作为保护相关性。
mBio. 2018 Jan 23;9(1):e02284-17. doi: 10.1128/mBio.02284-17.
4
Immunisation of 4-6 month old Gambian infants with Edmonston-Zagreb measles vaccine.用埃德蒙斯顿- Zagreb麻疹疫苗对4至6个月大的冈比亚婴儿进行免疫接种。
Lancet. 1984 Oct 13;2(8407):834-7. doi: 10.1016/s0140-6736(84)90873-0.
5
[A study on the HA amount of HA influenza vaccination on efficacy and safety in infants].[关于婴儿甲型流感疫苗接种剂量对疗效和安全性影响的研究]
Kansenshogaku Zasshi. 2013 Mar;87(2):195-206. doi: 10.11150/kansenshogakuzasshi.87.195.
6
Avian influenza in ovo vaccination with replication defective recombinant adenovirus in chickens: vaccine potency, antibody persistence, and maternal antibody transfer.鸡胚中使用复制缺陷型重组腺病毒进行禽流感疫苗接种：疫苗效力、抗体持久性和母源抗体传递
Avian Dis. 2011 Jun;55(2):285-92. doi: 10.1637/9600-112210-Reg.1.
7
Antibody persistence and serological protection among seasonal 2007 influenza A(H1N1) infected subjects: Results from the FLUREC cohort study.季节性 2007 年甲型 H1N1 流感感染人群中的抗体持久性和血清学保护：来自 FLUREC 队列研究的结果。
Vaccine. 2015 Dec 8;33(49):7015-21. doi: 10.1016/j.vaccine.2015.09.016. Epub 2015 Sep 19.
8
Influenza vaccination of dialysis patients: cross-reactivity of induced haemagglutination-inhibiting antibodies to H3N2 subtype antigenic variants is comparable with the response of naturally infected young healthy adults.透析患者的流感疫苗接种：诱导的血凝抑制抗体对H3N2亚型抗原变异株的交叉反应与自然感染的年轻健康成年人的反应相当。
Nephrol Dial Transplant. 2003 Apr;18(4):777-81. doi: 10.1093/ndt/gfg012.
9
Characterization of the M2e antibody response following highly pathogenic H5N1 avian influenza virus infection and reliability of M2e ELISA for identifying infected among vaccinated chickens.高致病性H5N1禽流感病毒感染后M2e抗体反应的特征以及M2e ELISA在识别接种疫苗鸡群中感染鸡方面的可靠性
Avian Pathol. 2015;44(4):259-68. doi: 10.1080/03079457.2015.1042428.
10
Virus-neutralizing antibody response of mice to consecutive infection with human and avian influenza A viruses.小鼠对人源和禽源甲型流感病毒连续感染的病毒中和抗体反应。
Acta Virol. 2015 Jun;59(2):166-73. doi: 10.4149/av_2015_02_166.
引用本文的文献
1
Insights in AAV-mediated antigen-specific immunity and a strategy for AAV vaccine dose reduction through AAV-extracellular vesicle association.腺相关病毒介导的抗原特异性免疫的见解以及通过腺相关病毒与细胞外囊泡结合来降低腺相关病毒疫苗剂量的策略。
Mol Ther Methods Clin Dev. 2024 Oct 18;32(4):101358. doi: 10.1016/j.omtm.2024.101358. eCollection 2024 Dec 12.
2
Intracellular develops enhanced fluoroquinolone persistence during influenza A coinfection.在甲型流感病毒合并感染期间，细胞内会产生增强的氟喹诺酮类药物持续性。
Front Microbiol. 2024 Jul 5;15:1423995. doi: 10.3389/fmicb.2024.1423995. eCollection 2024.
3
Have Diagnostics, Therapies, and Vaccines Made the Difference in the Pandemic Evolution of COVID-19 in Comparison with "Spanish Flu"?与“西班牙流感”相比，诊断方法、治疗手段和疫苗对新冠疫情演变产生了影响吗？
Pathogens. 2023 Jun 23;12(7):868. doi: 10.3390/pathogens12070868.
4
A protective measles virus-derived vaccine inducing long-lasting immune responses against influenza A virus H7N9.一种源自麻疹病毒的保护性疫苗，可诱导针对甲型流感病毒H7N9的持久免疫反应。
NPJ Vaccines. 2023 Mar 24;8(1):46. doi: 10.1038/s41541-023-00643-9.
5
Vaccination into the Dermal Compartment: Techniques, Challenges, and Prospects.真皮层接种疫苗：技术、挑战与前景
Vaccines (Basel). 2020 Sep 16;8(3):534. doi: 10.3390/vaccines8030534.
6
Challenges of Making Effective Influenza Vaccines.制作有效流感疫苗的挑战。
Annu Rev Virol. 2020 Sep 29;7(1):495-512. doi: 10.1146/annurev-virology-010320-044746. Epub 2020 May 11.
7
The Future of Flu: A Review of the Human Challenge Model and Systems Biology for Advancement of Influenza Vaccinology.流感的未来：人类挑战模型和系统生物学在流感疫苗学中的应用综述。
Front Cell Infect Microbiol. 2019 Apr 17;9:107. doi: 10.3389/fcimb.2019.00107. eCollection 2019.
8
Antibody levels in a cohort of pregnant women after the 2009 influenza A(H1N1) pandemic: Waning and association with self-reported severity and duration of illness.2009 年甲型 H1N1 流感大流行后孕妇队列的抗体水平：衰减及与自报疾病严重程度和持续时间的关系。
Influenza Other Respir Viruses. 2019 Mar;13(2):191-200. doi: 10.1111/irv.12623. Epub 2019 Jan 1.
9
Influenza vaccination and the 'diversity paradox'.流感疫苗接种与“多样性悖论”。
Hum Vaccin Immunother. 2018;14(12):3005-3009. doi: 10.1080/21645515.2018.1504596. Epub 2018 Sep 21.
10
Immunogenicity, safety and tolerability of intradermal influenza vaccines.皮内流感疫苗的免疫原性、安全性和耐受性。
Hum Vaccin Immunother. 2018 Mar 4;14(3):565-570. doi: 10.1080/21645515.2017.1328332. Epub 2017 Jul 6.
本文引用的文献
1
STUDIES WITH HUMAN INFLUENZA VIRUS CULTIVATED IN ARTIFICIAL MEDIUM.在人工介质中培养的人流感病毒研究。
J Exp Med. 1936 May 31;63(6):803-11. doi: 10.1084/jem.63.6.803.
2
THE INCIDENCE OF NEUTRALIZING ANTIBODIES FOR HUMAN INFLUENZA VIRUS IN THE SERUM OF HUMAN INDIVIDUALS OF DIFFERENT AGES.不同年龄段人群血清中针对人类流感病毒的中和抗体发生率。
J Exp Med. 1936 Apr 30;63(5):655-68. doi: 10.1084/jem.63.5.655.
3
IMMUNOLOGICAL STUDIES WITH THE VIRUS OF INFLUENZA.流感病毒的免疫学研究。
J Exp Med. 1935 Sep 30;62(4):505-16. doi: 10.1084/jem.62.4.505.
4
CULTIVATION OF HUMAN INFLUENZA VIRUS IN AN ARTIFICIAL MEDIUM.在人工培养基中培养人类流感病毒。
Science. 1935 Oct 11;82(2128):353-4. doi: 10.1126/science.82.2128.353.
Zotero 插件